Medical Background of the Alzheimer Type Dementia Alzheimer's disease (AD) and senile dementia of Alzheimer type (SDAT) are now universally concerned, and the prevention and therapy for these are most important. However, we have no concrete procedure for it. AD (and SDAT)has hitherto been mainly treated by the psychiatrists inJapan. But recent progress of image diagnosis and biochemical and immunological methods revealed manyof neweraspects of this disease, and in these points, cooperative study with the internists and neurologists is indispensable. AD(or SDAT)is a disease in which abnormality is confined within the central nervous system, and indeed, we have not found any visceral or generalized abnormalities specific for this disease. But recently immunological studies by Khansari et al. (J. Neuroimmunol. 7: 279-285, 1985) showed a severely low production of Interleukin-1 by patients peripheral blood monocytes and significant decrease of the number of autologous rosette forming cells (ARFC). These data suggest a profound immunological deficit in AD. Autoimmunemechanism for ADhas been postulated from the following points: high incidence of the disease in female, the late onset, familial incidence and presence of amyloid in the core of senile plaques, and a tendency of familial clustering of autoimmunedisorders such as lymphomaor thyroid disease. But, real correlation of these autoimmunephenomena to the brain pathology of ADis not clear. Pouplard et al. (Rev. Neurol. 139: 187-191, 1983) detected anti-prolactin-cell antibody in 96%
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of 27 cases of AD, and in similar frequency of the patients with Down's syndrome.
Tiggelen (J. Orthomolecular Psychiatr. 13: 97-104, 1983 ) demonstrated, in AD patients, low level of vitamin B12 in CSF despite of normal serum B12 level and significant increase in the ratio of serum Cu/serumZn, whenit comparedwith those of patients with multi-infarct dementia as well as with a matched control group. The meaning of this finding is not so clear, though some abnormal mechanism of vitamin B12 metabolism and zinc deficiency in this disease maybe suggested. On the other hand, aluminium (Al) has been implicated already in the pathogenesis of AD. This way of thinking is not always properly appreciated, but it is important that Al may change the blood brain barrier function and permit any of toxic substances including Al penetrate into the brain (Banks, W.A. et al.: Lancet, i i : 1227 -1229 , 1983 ).
We have measured neurotransmitters and neuropeptides in the cerebrospinal fluid (CSF) of the patients with AD, SDAT, and multi-infarct dementia as well as controls (Nakamura, S. et al.: Jpn. J. Med. 25: 87-89, 1986) . In CSF of AD, decrease of acetylcholinesterase, dopamine-|3-hydroxylase and glutamic acid decarboxylase activity, and of homovanillic acid and 5-hydroxyindole acetic acid were proved. Vasopr6s$ion decreased in SDAT.But CSF study is not proper way for screening ADor SDAT in the routine clinical works.
Recently, Atack et al. (J. Neurol. Sci. 70: 1-12, 1985) reported that plasma acetylcholinesterase (AChE) activity is significantly elevated in the ADand SDATgroup as compared with the control and other clinical groups. They postulated that the increase of AChEin the plasma is due to increased release from degenerating cholinergic neurons. If the methodto measure plasma AChEcan be more simplified, the measurement of plasma AChEmay be an important procedure for early and accurate
